NCT02389517View on ClinicalTrials.gov

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 2, 2015

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Plasma Cell MyelomaResidual Disease
Interventions
DRUG

Ixazomib Citrate

Given PO

DRUG

Lenalidomide

Given PO

DRUG

Dexamethasone

Given PO

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Multiple Myeloma Research Foundation

OTHER

lead

University of Chicago

OTHER